|
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 MARKET SIZE ESTIMATION
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.3 MARKET SHARE ESTIMATION
2.4 KEY DATA FROM SECONDARY SOURCES
2.5 KEY DATA FROM PRIMARY SOURCES
2.6 KEY INDUSTRY INSIGHTS
2.7 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 VACCINES MARKET HAS HIGH GROWTH POTENTIAL
4.2 VACCINES MARKET, BY TYPE
4.3 VACCINES MARKET, BY REGION
4.4 VACCINES MARKET, BY DISEASE INDICATION
4.5 VACCINES MARKET, BY END USER
4.6 LIFECYCLE ANALYSIS, BY REGION
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET SEGMENTATION
5.2.1 VACCINES MARKET, BY TECHNOLOGY
5.2.2 VACCINES MARKET, BY TYPE
5.2.3 VACCINES MARKET, BY DISEASE INDICATION
5.2.4 VACCINES MARKET, BY END USER
5.2.5 VACCINES MARKET, BY REGION
5.3 MARKET DYNAMICS
5.3.1 DRIVERS
5.3.1.1 High prevalence of diseases
5.3.1.2 Rising government and nongovernment funding for vaccine development
5.3.1.3 Increasing investments by companies
5.3.1.4 Technological advancements
5.3.2 RESTRAINTS
5.3.2.1 Huge capital investments
5.3.2.2 Stringent regulatory procedures
5.3.3 OPPORTUNITIES
5.3.3.1 High growth prospects in emerging markets
5.3.3.2 Therapeutic vaccines
5.3.3.3 Adjuvant vaccines
5.3.4 CHALLENGES
5.3.4.1 Inadequate access to vaccines
5.3.4.2 Vaccine pricing
5.3.5 BURNING ISSUES
5.3.5.1 Failure of vaccines
6 INDUSTRY INSIGHTS
6.1 PORTER’S FIVE FORCES ANALYSIS
6.1.1 THREAT FROM NEW ENTRANTS
6.1.2 BARGAINING POWER OF SUPPLIERS
6.1.3 BARGAINING POWER OF BUYERS
6.1.4 INTENSITY OF COMPETITIVE RIVALRY
6.1.5 THREAT OF SUBSTITUTES
6.2 VALUE CHAIN ANALYSIS
6.3 SUPPLY CHAIN ANALYSIS
6.4 TECHNOLOGY TRENDS FOR ADJUVANTS
6.4.1 DRIVERS
6.4.1.1 Increasing Use of Adjuvants in Vaccine-preventable Diseases
6.4.1.2 Rising Government Investments
6.4.2 RESTRAINS
6.4.2.1 High Cost of Research
6.4.2.2 Regulatory Hurdles
6.4.3 OPPORTUNITIES
6.4.3.1 Combined Adjuvants
6.4.3.2 Vaccines for Young Children
6.4.3.3 Pandemic Diseases
6.4.4 CHALLENGES
6.4.4.1 Identification of Adjuvants
6.4.4.2 Technological Limitations
6.4.5 TRENDS
6.4.5.1 Collaborations
6.4.5.2 New Adjuvant Technologies
6.5 INVESTMENT ANALYSIS
6.6 REGULATORY LANDSCAPE
6.6.1 NORTH AMERICA
6.6.2 EUROPE
6.6.3 ASIA
6.6.4 ROW
6.7 PATENT ANALYSIS
6.8 KEY PIPELINE PRODUCTS
6.9 STRATEGIC BENCHMARKING
7 VACCINES MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 SUBUNIT VACCINES
7.3 LIVE ATTENUATED VACCINES
7.4 CONJUGATE VACCINES
7.5 INACTIVATED VACCINES
7.6 RECOMBINANT VECTOR VACCINES
7.7 TOXOID VACCINES
7.8 SYNTHETIC VACCINES
7.9 DENDRITIC CELL VACCINES
8 VACCINES MARKET, BY TYPE
8.1 INTRODUCTION
8.2 PREVENTIVE VACCINES
8.3 THERAPEUTIC VACCINES
9 VACCINES MARKET, BY DISEASE INDICATION
9.1 INTRODUCTION
9.2 INFECTIOUS DISEASES
9.2.1 PNEUMOCOCCAL
9.2.2 INFLUENZA
9.2.3 DTP
9.2.4 HEPATITIS
9.2.5 ROTAVIRUS
9.2.6 VARICELLA
9.2.7 MENINGOCOCCAL
9.2.8 POLIO
9.2.9 MMR
9.2.10 OTHERS
9.3 CANCER
9.3.1 CERVICAL CANCER
9.3.2 OTHER CANCERS
9.4 ALLERGIES
10 VACCINES MARKET, BY END USER
10.1 INTRODUCTION
10.2 PEDIATRICS
10.3 ADULTS
11 GLOBAL VACCINES MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 FRANCE
11.3.3 U.K.
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 REST OF EUROPE (ROE)
11.4 ASIA
11.4.1 JAPAN
11.4.2 CHINA
11.4.3 INDIA
11.4.4 REST OF ASIA (ROA)
11.5 REST OF THE WORLD (ROW)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 MARKET SHARE ANALYSIS
12.3 COMPETITIVE SITUATION AND TRENDS
12.3.1 AGREEMENTS, COLLABORATIONS, & PARTNERSHIPS
12.3.2 REGULATORY APPROVALS
12.3.3 ACQUISITIONS
12.3.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
13.1 INTRODUCTION
13.2 GLAXOSMITHKLINE, PLC.
13.3 MERCK & CO., INC.
13.4 SANOFI PASTEUR
13.5 PFIZER, INC.
13.6 NOVARTIS AG
13.7 BAVARIAN NORDIC
13.8 CSL LIMITED
13.9 EMERGENT BIOSOLUTIONS, INC.
13.10 JOHNSON & JOHNSON
13.11 MEDIMMUNE, LLC. (A SUBSIDIARY OF ASTRAZENECA)
*Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.
14 APPENDIX
14.1 RECENT DEVELOPMENTS
14.1.1 GLAXOSMITHKLINE, PLC.
14.1.2 SANOFI PASTEUR
14.1.3 NOVARTIS AG
14.1.4 EMERGENT BIOSOLUTIONS INC.
14.2 INSIGHTS FROM INDUSTRY EXPERTS
14.3 DISCUSSION GUIDE
14.4 AVAILABLE CUSTOMIZATIONS
14.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
14.6 RELATED REPORTS
LIST OF TABLES
TABLE 1 INCREASING PREVALENCE OF DISEASES TO BOOST THE MARKET GROWTH OF VACCINES
TABLE 2 HUGE CAPITAL INVESTMENT TO LIMIT THE MARKET GROWTH OF VACCINES
TABLE 3 INCREASING PREVALENCE OF DISEASES TO BOOST THE MARKET GROWTH OF VACCINES
TABLE 4 INCREASING PREVALENCE OF DISEASES TO BOOST THE MARKET GROWTH OF VACCINES
TABLE 5 NATIONAL INSTITUTES OF HEALTH (NIH) FUNDING FOR VACCINE DEVELOPMENT, 2011–2013 ($MILLION)
TABLE 6 REGULATORY AUTHORITIES IN EUROPE
TABLE 7 REGULATORY AUTHORITIES IN ASIA
TABLE 8 KEY PIPELINE VACCINES
TABLE 9 VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 10 SUBUNIT VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
TABLE 11 NORTH AMERICA: SUBUNIT VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 12 EUROPE: SUBUNIT VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 13 ASIA: SUBUNIT VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 14 LIVE ATTENUATED VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
TABLE 15 NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 16 EUROPE: LIVE ATTENUATED VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 17 ASIA: LIVE ATTENUATED VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 18 CONJUGATE VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
TABLE 19 NORTH AMERICA: CONJUGATE VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 20 EUROPE: CONJUGATE VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 21 ASIA: CONJUGATE VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 22 INACTIVATED VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
TABLE 23 NORTH AMERICA: INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 24 EUROPE: INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 25 ASIA: INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 26 RECOMBINANT VECTOR VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
TABLE 27 NORTH AMERICA: RECOMBINANT VECTOR VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 28 EUROPE: RECOMBINANT VECTOR VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 29 ASIA: RECOMBINANT VECTOR VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 30 TOXOID VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
TABLE 31 NORTH AMERICA: TOXOID VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 32 EUROPE: TOXOID VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 33 ASIA: TOXOID VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 34 SYNTHETIC VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
TABLE 35 NORTH AMERICA: SYNTHETIC VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 36 EUROPE: SYNTHETIC VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 37 ASIA: SYNTHETIC VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 38 DENDRITIC CELL VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
TABLE 39 NORTH AMERICA: DENDRITIC CELL VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 40 EUROPE: DENDRITIC CELL VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 41 ASIA: DENDRITIC CELL VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 42 VACCINES MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
TABLE 43 PREVENTIVE VACCINES MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
TABLE 44 NORTH AMERICA: PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 45 EUROPE: PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 46 ASIA: PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 47 THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
TABLE 48 NORTH AMERICA: THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 49 EUROPE: THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 50 ASIA: THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 51 VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012–2019 ($MILLION)
TABLE 52 VACCINES MARKET SIZE FOR INFECTIOUS DISEASES, BY REGION, 2012-2019 ($MILLION)
TABLE 53 NORTH AMERICA: VACCINES MARKET SIZE FOR INFECTIOUS DISEASES, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 54 EUROPE: VACCINES MARKET SIZE FOR INFECTIOUS DISEASES, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 55 ASIA: VACCINES MARKET SIZE FOR INFECTIOUS DISEASES, BY COUNTRY, 2012-2019 ($MILLION)
TABLE 56 INFECTIOUS DISEASES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 57 VACCINES MARKET SIZE FOR CANCER, BY REGION, 2012–2019 ($MILLION)
TABLE 58 NORTH AMERICA: VACCINES MARKET SIZE FOR CANCER, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 59 EUROPE: VACCINES MARKET SIZE FOR CANCER, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 60 ASIA: VACCINES MARKET SIZE FOR CANCER, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 61 CANCER VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 62 VACCINES MARKET SIZE FOR ALLERGIES, BY REGION, 2012–2019 ($MILLION)
TABLE 63 NORTH AMERICA: VACCINES MARKET SIZE FOR ALLERGIES, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 64 EUROPE: VACCINES MARKET SIZE FOR ALLERGIES, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 65 ASIA: VACCINES MARKET SIZE FOR ALLERGIES, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 66 VACCINES MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
TABLE 67 VACCINES MARKET SIZE FOR PEDIATRICS, BY REGION, 2012–2019 ($MILLION)
TABLE 68 NORTH AMERICA: VACCINES MARKET SIZE FOR PEDIATRICS, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 69 EUROPE: VACCINES MARKET SIZE FOR PEDIATRICS, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 70 ASIA: VACCINES MARKET SIZE FOR PEDIATRICS, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 71 VACCINES MARKET SIZE FOR ADULTS, BY REGION, 2012–2019 ($MILLION)
TABLE 72 NORTH AMERICA: VACCINES MARKET SIZE FOR ADULTS, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 73 EUROPE: VACCINES MARKET SIZE FOR ADULTS, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 74 ASIA: VACCINES MARKET SIZE FOR ADULTS, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 75 VACCINES MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
TABLE 76 NORTH AMERICA: VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 77 EUROPE: VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 78 ASIA: VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
TABLE 79 NORTH AMERICA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 80 NORTH AMERICA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 81 NORTH AMERICA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 82 NORTH AMERICA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
TABLE 83 U.S.: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 84 U.S.: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 85 U.S.: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 86 U.S.: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
TABLE 87 CANADA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 88 CANADA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 89 CANADA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 90 CANADA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
TABLE 91 EUROPE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 92 EUROPE: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 93 EUROPE: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 94 EUROPE: VACCINES MARKET SIZE, BY END USERS, 2012-2019 ($MILLION)
TABLE 95 GERMANY: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 96 GERMANY: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 97 GERMANY: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 98 GERMANY: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
TABLE 99 FRANCE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 100 FRANCE: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 101 FRANCE: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 102 FRANCE: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
TABLE 103 U.K.: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 104 U.K.: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 105 U.K.: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 106 U.K.: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
TABLE 107 ITALY: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 108 ITALY: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 109 ITALY: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 110 ITALY: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
TABLE 111 SPAIN: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 112 SPAIN: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 113 SPAIN: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 114 SPAIN: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
TABLE 115 ROE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 116 ROE: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 117 ROE: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 118 ROE: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
TABLE 119 ASIA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 120 ASIA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 121 ASIA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 122 ASIA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
TABLE 123 JAPAN: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 124 JAPAN: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 125 JAPAN: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 126 JAPAN: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
TABLE 127 CHINA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 128 CHINA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 129 CHINA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 130 CHINA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
TABLE 131 INDIA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 132 INDIA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 133 INDIA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 134 INDIA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
TABLE 135 ROA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 136 ROA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 137 ROA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 138 ROA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
TABLE 139 ROW: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
TABLE 140 ROW: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
TABLE 141 ROW: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
TABLE 142 ROW: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
TABLE 143 RECENT AGREEMENTS AND COLLABORATIONS
TABLE 144 RECENT REGULATORY APPROVALS
TABLE 145 RECENT ACQUISITIONS
TABLE 146 RECENT OTHER DEVELOPMENTS
TABLE 147 EXCHANGE RATES (UTILIZED FOR CONVERSION OF GBP TO USD)
TABLE 148 EXCHANGE RATES (UTILIZED FOR CONVERSION OF EURO TO USD)
TABLE 149 EXCHANGE RATES (UTILIZED FOR THE CONVERSION OF DKK TO USD)
LIST OF FIGURES
FIGURE 1 VACCINES MARKET, BY TECHNOLOGY
FIGURE 2 RESEARCH METHODOLOGY
FIGURE 1 TOP-DOWN APPROACH
FIGURE 2 BOTTOM-UP APPROACH
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 DATA TRIANGULATION METHODOLOGY
FIGURE 5 VACCINE TECHNOLOGY MARKET SNAPSHOT (2014 VS. 2019): SUBUNIT VACCINES TO GROW AT HIGHEST CAGR
FIGURE 6 PREVENTIVE VACCINES TO DOMINATE THE VACCINES MARKET
FIGURE 7 PEDIATRIC SEGMENT WILL BE THE LARGEST END-USER SEGMENT IN THE VACCINES MARKET
FIGURE 8 NORTH AMERICA TO HOLD LARGEST SHARE IN THE GLOBAL VACCINES MARKET
FIGURE 9 HIGH PREVALENCE OF DISEASES TO DRIVE MARKET GROWTH
FIGURE 10 PREVENTIVE VACCINES SEGMENT HELD THE LARGEST SHARE IN VACCINES MARKET, BY TYPE
FIGURE 11 U.S. COMMANDS ONE-THIRD OF THE MARKET
FIGURE 12 INFECTIOUS DISEASES SEGMENT TO WITNESS SIGNIFICANT GROWTH IN EMERGING ECONOMIES
FIGURE 13 PEDIATRICS SEGMENT WILL CONTINUE TO LEAD THE VACCINES END-USERS MARKET DURING THE FORECAST PERIOD
FIGURE 14 ASIA TO WITNESS HIGH GROWTH RATE IN THE VACCINES MARKET DURING FORECAST PERIOD
FIGURE 15 VACCINES MARKET SEGMENTATION: BY TECHNOLOGY
FIGURE 16 VACCINES MARKET SEGMENTATION: BY TYPE
FIGURE 17 VACCINES MARKET SEGMENTATION: BY DISEASE INDICATION
FIGURE 18 VACCINES MARKET SEGMENTATION: BY END USER
FIGURE 19 VACCINES MARKET SEGMENTATION: BY REGION
FIGURE 20 INCREASING GOVERNMENT SUPPORT FOR PANDEMIC THREATS LIKELY TO FUEL GROWTH OF VACCINES MARKET
FIGURE 21 PORTER’S FIVE FORCES ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE DEVELOPMENT AND MANUFACTURING PHASES
FIGURE 23 SUPPLY CHAIN ANALYSIS
FIGURE 24 COLD CHAIN MANAGEMENT
FIGURE 25 FDA-APPROVED VACCINE ADJUVANTS
FIGURE 26 LICENSED VACCINES CONTAINING ADJUVANTS
FIGURE 27 EXAMPLES OF VACCINE ADJUVANTS IN CLINICAL TRIALS
FIGURE 28 INVESTORS PLAY AN IMPORTANT ROLE IN THE VACCINES MARKET
FIGURE 29 VACCINE RESEARCH FUNDING, BY TYPE OF INVESTOR
FIGURE 30 U.S. GOVERNMENT AGENCIES HELD LARGEST SHARE OF THE HIV R&D FUNDING IN 2013
FIGURE 31 REGULATORY APPROVAL PROCESS FOR VACCINES
FIGURE 32 NORTH AMERICA ACCOUNTED FOR THE LARGEST NUMBER OF PATENT FILINGS IN 2012
FIGURE 33 THE U.S. ACCOUNTED FOR LARGEST NUMBER OF PATENT FILINGS ACROSS THE GLOBE (2012)
FIGURE 34 STRATEGIC BENCHMARKING: GLAXOSMITHKLINE, PLC. LARGELY ADOPTED INORGANIC GROWTH STRATEGIES FOR ENHANCING PRODUCT OFFERINGS
FIGURE 35 SUBUNIT VACCINES SEGMENT TO GROW AT HIGHEST CAGR IN FORECAST PERIOD
FIGURE 36 NORTH AMERICA TO DOMINATE THE INACTIVATED VACCINES MARKET FROM 2014 TO 2019
FIGURE 37 TOXOID VACCINES MARKET IN ASIA WILL GROW AT HIGHEST CAGR FROM 2014 TO 2019
FIGURE 38 PREVENTIVE VACCINES TO DOMINATE THE GLOBAL VACCINES MARKET FROM 2014 TO 2019
FIGURE 39 ASIA TO GROW AT THE HIGHEST CAGR FROM 2014 TO 2019
FIGURE 40 INFECTIOUS DISEASES SEGMENT TO DOMINATE THE VACCINES MARKET FROM 2014 TO 2019
FIGURE 41 THE PEDIATRICS END-USER SEGMENT WILL DRIVE THE VACCINES MARKET DURING THE FORECAST PERIOD
FIGURE 42 GEOGRAPHIC SNAPSHOT (2014): EMERGING MARKETS HOLD GROWTH OPPORTUNITIES
FIGURE 43 GEOGRAPHIC BENCHMARKING FOR VACCINES TECHNOLOGY MARKET
FIGURE 44 MARKET GROWTH WILL BE DRIVEN BY INCREASING R&D ACTIVITIES FOR DEVELOPMENT OF VACCINES
FIGURE 45 INFECTIOUS DISEASES SEGMENT WILL CONTINUE TO DRIVE THE VACCINES MARKET
FIGURE 46 GERMANY WILL CONTINUE TO DOMINATE THE VACCINES MARKET IN EUROPE
FIGURE 47 GERMAN VACCINES MARKET TO GROW AT THE HIGHEST CAGR IN EUROPE
FIGURE 48 VACCINES MARKET IN ASIA GROW AT THE HIGHEST CAGR
FIGURE 49 INDIAN VACCINES MARKET WILL HAVE HIGH GROWTH POTENTIAL
FIGURE 50 PREVENTIVE VACCINES WILL LEAD THE ROW VACCINES MARKET IN 2019
FIGURE 51 MAJOR PLAYERS SIGNED AGREEMENTS TO ENHANCE THEIR MARKET POSITIONS IN THE VACCINES MARKET
FIGURE 52 VACCINES MARKET SHARE, BY KEY PLAYER, 2013
FIGURE 53 BATTLE FOR MARKET SHARE: AGREEMENTS WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS
FIGURE 54 PRODUCT BENCHMARKING FOR TOP 5 MARKET PLAYERS
FIGURE 55 GLAXOSMITHKLINE, PLC.: COMPANY SNAPSHOT
FIGURE 56 MERCK & CO., INC.: COMPANY SNAPSHOT
FIGURE 57 SANOFI PASTEUR: COMPANY SNAPSHOT
FIGURE 58 PFIZER INC.: COMPANY SNAPSHOT
FIGURE 59 NOVARTIS AG: COMPANY SNAPSHOT
FIGURE 60 BAVARIAN NORDIC: COMPANY SNAPSHOT
FIGURE 61 CSL LIMITED: COMPANY SNAPSHOT
FIGURE 62 EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT
FIGURE 63 JOHNSON & JOHNSON: COMPANY SNAPSHOT
FIGURE 64 ASTRAZENECA : COMPANY SNAPSHOT
|
현재위치 : 
